88182

Flow Cytometry, Additional Marker

Flow cytometry (CPT 88182, in conjunction with 88180 for the first eight markers or itself for subsequent additional markers) is an advanced laboratory technique employed for the rapid, quantitative, and qualitative analysis of individual cells suspended in a fluid. The process involves directing a single-file stream of cells through one or more laser beams. As each cell passes, it scatters light and emits fluorescence from attached fluorochrome-conjugated antibodies that bind to specific cellular components or surface antigens. Detected signals provide information about the cell's physical properties (size and granularity via scattered light) and its immunophenotype (presence and intensity of specific antigens via fluorescence). This multiparametric analysis enables the precise identification, enumeration, and characterization of diverse cell populations within complex biological samples, such as peripheral blood, bone marrow aspirates, cerebrospinal fluid, or disaggregated tissue. The technology is indispensable in hematopathology and immunology for the diagnosis, classification, and monitoring of hematologic malignancies (e.g., leukemias, lymphomas, myelodysplastic syndromes), assessment of immunodeficiency states (e.g., HIV/AIDS, primary immunodeficiencies), detection of minimal residual disease (MRD), and evaluation of post-transplant engraftment. CPT 88182 specifically covers the analysis of *each additional* cellular marker beyond the first eight conducted within a single flow cytometric analysis. The extent and type of markers utilized are tailored to the specific clinical query, often involving extensive immunophenotyping panels for accurate cellular lineage assignment and identification of aberrant populations.

Clinical Indications

  • Diagnosis, classification, and staging of acute leukemias (AML, ALL).
  • Diagnosis and subclassification of chronic lymphoproliferative disorders (e.g., CLL, Hairy Cell Leukemia, MCL).
  • Diagnosis and staging of non-Hodgkin and Hodgkin lymphomas on body fluids or disaggregated tissue.
  • Diagnosis and monitoring of plasma cell dyscrasias (e.g., Multiple Myeloma, MGUS).
  • Detection and monitoring of minimal residual disease (MRD) in hematologic malignancies post-treatment.
  • Evaluation of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).
  • Assessment of immunodeficiency disorders, including HIV/AIDS monitoring (e.g., CD4 counts), severe combined immunodeficiency (SCID), and common variable immunodeficiency (CVID).
  • Diagnosis of paroxysmal nocturnal hemoglobinuria (PNH).
  • Monitoring of bone marrow or stem cell transplant engraftment and rejection.
  • Detection of fetal-maternal hemorrhage (FMH).
  • Quantification of T, B, and NK cell populations and their subsets (e.g., regulatory T cells).
  • Diagnosis and follow-up of autoimmune lymphoproliferative syndrome (ALPS).

Procedure Steps

  1. Sample Collection and Preparation: Collect peripheral blood, bone marrow aspirate, lymph node biopsy, fresh tissue, cerebrospinal fluid, or other body fluid. Cells are typically separated from red blood cells (lysis) and washed. Solid tissues may require mechanical and enzymatic disaggregation to obtain a single-cell suspension.
  2. Cell Staining: Aliquots of the prepared cell suspension are incubated with a panel of fluorescently-labeled monoclonal antibodies targeting specific cell surface or intracellular antigens. The number of markers depends on the diagnostic question and the specific panel designed.
  3. Data Acquisition (Flow Cytometer): Stained cells are introduced into the flow cytometer, where they are hydrodynamically focused to pass single file through one or more laser beams. Light scatter and fluorescence signals from each cell are detected by an array of detectors.
  4. Signal Conversion and Digitalization: Analog signals from the detectors are converted into digital data, representing parameters such as forward scatter (FSC), side scatter (SSC), and multiple fluorescence intensities (e.g., FL1, FL2, FL3, FL4, corresponding to different fluorochromes).
  5. Data Analysis: Raw data is displayed as dot plots and histograms using specialized software. Gating strategies are applied to define specific cell populations based on their light scatter properties and expression of various markers. For each population, the percentage of cells positive for particular markers and their mean fluorescence intensity are determined.
  6. Interpretation and Reporting: A pathologist or trained physician interprets the findings in correlation with clinical information, patient history, and other laboratory results. A comprehensive report is generated, including cell percentages, absolute counts, immunophenotypic profile, and diagnostic conclusions.

Coding Guidelines

  • CPT code 88182 is an add-on code and must always be billed in conjunction with CPT 88180 (Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component; first 8 markers) or 88182 itself for a panel exceeding 8 markers.
  • The primary code for the first 8 markers is 88180. If more than 8 markers are analyzed, 88182 is used for *each additional marker*. For example, if 10 markers are analyzed, report 88180 for the first 8 markers and 88182 for the 2 additional markers (billed as 88182 x 2 units).
  • These codes (88180, 88182) represent the *technical component* of the flow cytometry service, which includes sample preparation, instrument operation, data acquisition, and initial analysis.
  • The *professional component* (interpretation and report by a physician) is separately coded using 88187 (Flow cytometry, interpretation and report; 2 to 8 markers), 88188 (Flow cytometry, interpretation and report; 9 to 15 markers), or 88189 (Flow cytometry, interpretation and report; 16 or more markers).
  • Careful documentation of the number of distinct markers performed and analyzed is crucial for accurate billing.
  • Do not report 88180, 88182, 88187, 88188, or 88189 when reporting 88172 (Cytopathology, evaluation of fine needle aspirate; immediate cytological study to determine adequacy for diagnosis, an independent physician interpretation and report, per collection site).
  • Bundling: These codes are generally not bundled with other distinct pathology procedures when performed for different purposes. However, it's essential to check payer-specific policies regarding multiple flow cytometry panels on the same date of service or for different specimens.

Associated ICD-10 Codes